The problem of tumor cell drug resistance remains a barrier to II) RNA expression (Northern, slot-blot, RT-PCR, in situ PCR) and
cytometry) can all give varying results, especially when attempting to detect low levels of over-and underexpressed proteins. Complicating the situation are differences in Introduction methods of tissue fixation, reagents used for primary and secondary detection, and controls used to calibrate various The problem of drug resistance continues to pose an important systems. barrier to the cure of neoplastic diseases. Two major impediIn this paper, the problems inherent in identifying drug ments to surmounting this problem remain the identification resistance-associated genes and gene products in patients' of all the proteins involved in cellular resistance, and, remarktumors will be discussed briefly. Key considerations necessary ably, accurate methods to detect these proteins. Over the past for the standardized detection of these proteins will be sumseveral years, it has become clear that the cellular basis of marized; these were developed from a workshop devoted to antitumor drug resistance, at least that in patients' tumors, is a the detection of Pgp/MDR in patients' tumors. The problem of inter-and intra-assay variability in is also clear that the insensitivity of cells selected for resistance detecting genes and proteins associated with drug to a single agent is not necessarily only a function of the target resistance gene. Indeed, it has been shown that drug resistance in mammalian cells is associated with altered expression of proto-
The above-mentioned problems in detection of MDR markers oncogenes, 3 and can involve cell cycle regulatory genes, 4 and in clinical specimens, notably Pgp, led to the development genes involved in regulation of the phenomenon of proof the Multidrug Resistance Detection Methods Workshop in grammed cell death (PCD), also known as apoptosis. 5 Memphis, Tennessee in 1994.
11 Specifically, this Workshop With this panoply of disregulated genes contributing to the was prompted and driven by the variability of study results drug resistance phenotype of a tumor, it is difficult to assess among different laboratories in attempting to assess the importhe individual importance of any of them. Those genes that tance of the MDR1 gene product, Pgp, in clinical oncology, are targets for drugs, ie those that confer drug resistance and especially in the poor response of some tumors to chemobecause they attenuate the cytotoxic response of drugs therapy. 12,13 It was evident that there was little or no staninclude: (1) MDR1, which encodes the drug efflux pump, Pdardized methodology to assess expression of Pgp and MDR1, glycoprotein (Pgp 1 ); (2) the gene for the multidrug resistanceas different laboratories used immunostaining, immunohistoassociated protein (MRP), which encodes another efflux chemistry, immunocytochemistry, flow cytometry, Western pump; 2 and (3) the lung tumor resistance-associated protein, blotting, Northern blotting, and RT-PCR. Moreover, few lab-LRP, which is one of the major vault proteins. 6 Other genes, oratories attempted to correlate these protein and RNA data while not conferring MDR, do render tumor cells resistant to to functional studies of drug resistance.
14-16 specific drugs or drug classes when overexpressed, underexThe Workshop identified several factors that appeared to pressed, or mutated. They include: (1) topoisomerase I (topo influence the detection of Pgp in clinical specimens, 11 includ-I) and camptothecin resistance; 7 (2) topoisomerase II␣ (topo ing:
(1) low and heterogeneous levels of Pgp expression (higher levels of Pgp can be reliably detected by most laboratories, formly defined and quantitated);
(2) different detection end-points (most often seen as Antibodies semiquantitative assessments of intensity of immunostaining, although results have also been expressed as intensity Another critically important component of the system is the specificity and quality of the primary (anti-Pgp) antibodies. of bands on immuno-or RNA blots, which do not account for tumor cell heterogeneity);
The Workshop recommended that at least two antibodies recognizing different epitopes on Pgp would provide (3) differences in clinical end-points (eg time to relapse, survival, functional Pgp assays, etc); reliability of the assay and diminish the possibility of detection of an irrelevant epitope or protein.
Moreover, the quality of (4) differences in the methods by which samples are prepared, fixed, and analyzed for either immunodetection or commercially available antibodies was regarded as a potential confounding variable. Accordingly, the Workshop partiflow cytometry; (5) differences in immunologic reagents that have variable cipants recommended that antibodies be standardized by vendors for epitope affinity and biochemical purity, that they be affinity for and recognition of Pgp epitopes; (6) use of different secondary antibodies and chromogens (eg standardized and calibrated against Pgp-expressing cell lines in several different assays, and the antibodies be shipped to alkaline phosphatase vs peroxidase); and also, as we have learned over the past several years, purchasers with these data as 'package inserts'. (7) mechanisms other than Pgp overexpression may contribute to clinical MDR, as discussed above (eg MRP, LRP, alterations in topo II, and altered expression of cell cycle Sample preparation or PCD proteins). Specific recommendations were made for sample preparation Among tumors with low expression of Pgp, a combination of and handling, and these differed somewhat depending on the these factors is likely to be important. Thus, because of these assay to be used. These were made for both histo-and cytomany variables, the primary goal of the Workshop was to offer chemistry as well as for flow cytometry. guidelines to normalize methods to detect Pgp Endpoints and reporting of data detection methods afforded more reliability and accuracy than 'bulk' methods such as immunoblots, Northerns, and RT-PCR Finally, a major confounding factor in interpreting the role of in that the former were generally able to discriminate tumor Pgp in clinical drug resistance, as indicated above, is the from normal cells. The primary methods for detection of Pgp variability of end-points and methods of reporting data. at the single-cell level are antibody-based: immunohistochemAccordingly, the Workshop addressed this issue and made ical or immunocytochemical staining or flow cytometry of specific recommendations. For immunostaining, the partispecimens. Although Workshop recommendations were made cipants advocated reporting both intensity of staining and perseparately for immunostaining and for flow cytometry, they centage of Pgp+ cells, since the value of either assessment will be summarized together here, since there is overlap and alone is currently not known. Furthermore, arbitrary minimal similarity among the recommendations for the two methods.
cut-off points were not recommended for use in data analysis. Both methods require the use of antibody reagents and caliWhile no specific recommendation could be made for flow bration controls, and key recommendations involved quality cytometry, it was suggested, as for immunostaining, that data control, calibration controls, and the antibodies.
be reported as continuous variables rather than imposing arbitrary cut-offs.
Calibration controls

Future considerations
While the St Jude Workshop focused on methods to detect One of the most important concepts to come from the Workshop, in our view, is the notion that all assays must be caliPgp, future efforts will likely require reliable detection of other drug resistance-associated proteins, such as MRP, 2 LRP, 6 topo brated using suitable cell lines with both negative and positive expression of MDR1/Pgp. The positive controls should be of II, 8 and markers of other forms of drug resistance such as dhfr, 9 mgmt, 10 and, eg, bcl-2 family members. 5 One of the key low but increasing expression of MDR1/Pgp. Without appropriate calibration controls, results from laboratory to laboraaccomplishments of the Workshop was the recognition of the need to standardize the various methodologies used to meastory would not be comparable; such calibration standards are also required because of inter-and intra-assay variability.
ure Pgp. It is the hope that future workshops will apply these protein (MRP) increases resistance to natural product drugs. Canlessons to the measurement of these other drug resistance- reliably to detect Pgp in patients' tumors. In summary, the rec- Leith CP, Paietta E, Pavelic ZP, Rimsza L, Roninson IB, Sikic BI, Twentyman PR, Warnke R, Weinstein R. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996; 56: 3010-3020.
